

Claim 13, line 1, change "8" to --16-- and "cells are" to --  
cell is a--; and

line 2, change "phagocytes" to --phagocyte--.

Claim 14, line 2, change "phagocytes are" to --phagocyte is  
a-- and change "monocytes" to --monocyte--.

Claim 15, line 1, change "8" to --16--.

Add the following new claims.

--16. A method of inhibiting CD44-facilitated HIV infection  
of a cell susceptible to HIV infection comprising contacting said  
cell with an amount of an anti-CD44 antibody sufficient to bind  
to CD44 molecules present on the surface of said cell and thereby  
inhibit said CD44-facilitated infection of said cell.

--17. The method according to claim 16 wherein said  
mononuclear phagocytes are ~~vaginal~~ mucosal cells.

18. The method according to claim 16 wherein said  
contacting is effected by topical administration.

*J. J. Weinberg*  
19. The method according to claim 16 wherein said cells are  
~~ex vivo~~ mononuclear phagocytes.----

IN THE ABSTRACT:

Substitute the Abstract of the Disclosure submitted herewith  
on a separate sheet for that originally filed.

REMARKS

Reconsideration of this application and entry of the  
foregoing amendments are respectfully requested.

Applicants hereby affirm the verbal election of the subject  
matter of Group I for prosecution in this application. The  
Examiner's comments on page 3 of the Action, third paragraph,  
regarding the rejoining of the subject matter of Groups II and  
III are noted but not understood. Clarification is respectfully  
requested.

The title has been revised in accordance with the Examiner's  
request.

The specification has been revised to correct errors and  
capitalize trademarks. The specification has also been revised  
to include Sequence ID numbers and to include a Sequence Listing.  
Submitted herewith is a computer-readable copy of that Listing